poisar

Stock

Immunome, Inc. IMNM

$26.63+0.78%

Overview

IMNM market data

Price History

IMNM price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.43
Diluted earnings per share over the trailing twelve months.
Beta
2.54
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,687.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$8.67 – $28.04
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $3B · P/B 3.74 · P/S 238.36.

Company News

10 captured
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38Benzinga · Aug 12, 2026, 5:27 PM
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35Benzinga · Aug 12, 2026, 4:09 PM
Immunome Q2 EPS $(0.65) Misses $(0.52) EstimateBenzinga · Aug 11, 2026, 8:34 PM
SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Aug 5, 2026, 12:03 PM
Wedbush Reiterates Outperform on Immunome, Maintains $31 Price TargetBenzinga · Jul 21, 2026, 1:33 PM
Immunome Announces First Patient Dosed In Phase 1 IM-3050 Trial To Treat FAP-Expressing Advanced Solid TumorsBenzinga · Jul 20, 2026, 11:34 AM
Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA ReviewBenzinga · Jul 8, 2026, 5:25 PM
Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action DateBenzinga · Jul 8, 2026, 11:35 AM
Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid TumorsBenzinga · Jun 11, 2026, 11:32 AM
Truist Securities Maintains Buy on Immunome, Raises Price Target to $37Benzinga · May 28, 2026, 4:04 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock